Multicenter, Postmarketing Assessment of Levofloxacin in the Treatment of Adults with Community-Acquired Pneumonia
Abstract
This phase IV, multicenter, open-label trial was designedto provide confirmation of the efficacy and safety of levofloxacin, 500 mg once daily, in a large population of “real-world” patients with community-acquired pneumonia(CAP). For 410 (24%) of the 1730 patients in the intent-to-treat population, a pathogen was identified by culture at admission. Of these pathogens, 262(64%) were Streptococcus pneumoniae, 85(21%) were Haemophilus influenzae, and 65 (16%) were Staphylococcus aureus. A total of 1095 patients in the intent-to-treat population were clinically evaluable, and the rate of clinical success for these patients was 94% (acure was achieved for 83% of the patients, and an improvement in condition was experienced by 11%). The clinical success rate for the 188 clinically evaluable patients with S. pneumoniae infections was 93%. The most-frequent adverse events that were considered to be treatment related were nausea (0.9%), rash (0.5%), diarrhea (0.4%), and vomiting (0.4%). The results of the present study confirm those of previous phase III clinical trials showing that levofloxacin, 500 mg once daily, is an effective and well-tolerated therapy for community-acquired pneumonia.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.